A Canadian class action lawsuit against Pfizer focusing on bone density loss concluded in 2021 with a $2.17 million settlement.
The current U.S. Depo-Provera MDL differs by exclusively addressing meningioma claims in women who used the injectable contraceptive for periods exceeding one year.
Legal experts anticipate that as the litigation unfolds and further medical research is conducted, the scope of qualifying injuries could broaden.
Canadian claimants received compensation based on documented bone density loss severity, with those showing steeper decreases and longer usage periods awarded higher amounts.
If you or someone you love has been diagnosed with meningioma (brain tumors) after using Depo-Provera, you may qualify to seek compensation.
Contact TruLaw using the chat on this page to receive an instant-case evaluation that can determine your eligibility to join others filing for the Depo-Provera MDL.